GDNF

Stem cells engineered to mature into nerve-supporting cells that produce GDNF — a key factor for motor neuron survival — were safely delivered into the spinal cord of people with amyotrophic lateral sclerosis (ALS), according to data from a Phase 1/2a clinical trial. These cells, dubbed CNS10-NPC-GDNF, were…

Cedars-Sinai Medical Center, in California, has been awarded an $11.99 million grant to support a clinical trial that will test specifically engineered neural progenitor cells as a potential therapy for amyotrophic lateral sclerosis (ALS). The work, funded by the California Institute for Regenerative Medicine, or CIRM, will build…

The Australian non-profit organization FightMND has awarded Lauren Sciences a AU$1 million ($710,000 US) grant to further the biotechnology company’s development of a new treatment for amyotrophic lateral sclerosis (ALS). Specifically, the New York-based biotechnology company will use the funds to advance LAUR-301, a medicine that aims…

Transplanting engineered neural cells into the brain of an amyotrophic lateral sclerosis (ALS) animal model delayed disease progression and extended the animals’ survival, a study shows. The study, “Transplantation of Neural Progenitor Cells Expressing Glial Cell Line‐Derived Neurotrophic Factor into the Motor Cortex as a Strategy to Treat Amyotrophic Lateral…

Treeway, a biotechnological company based in the Netherlands, founded by Bernard Muller and Robbert Jan Stuit, who are both entrepreneurs and both diagnosed with amyotrophic lateral sclerosis (ALS), recently announced a collaboration with uniQure, a Dutch company specialized in gene therapy to develop a treatment for the disease.